<scp>GPVI</scp> as a Potential New Biomarker for Myelofibrosis Diagnosis
Xavier Hittinger(Nantes Université), Marc Fouassier(Nantes Université), Antoine Babuty(Nantes Université), Patrice Chevallier(Centre Hospitalier Universitaire de Nantes), Marion Loirat(Centre Hospitalier Saint-Nazaire), Antoine Bonnet(Centre hospitalier Bretagne Atlantique), Simon Bouzy(Nantes Université), Bruno Villemagne(Centre Hospitalier Départemental Vendée), Raphaël Bourgade(Inserm), Romain Madeuf(Nantes Université), Sophie Vantyghem(Nantes Université), Y. Aiba(Nantes Université), Yannick Le Bris(Centre National de la Recherche Scientifique)
Cited by 0
Related Papers
Prognostic impact of<i>DDX41</i>germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study
|Blood|2022|80
Deep Learning Methodologies Applied to Digital Pathology in Prostate Cancer: A Systematic Review
|Diagnostics|2023|40
Significance of Measurable Residual Disease in Adult Philadelphia Chromosome–Positive ALL: A GRAAPH-2014 Study
|Journal of Clinical Oncology|2024|39
Concurrent <i>CDX2 cis</i>-deregulation and <i>UBTF::ATXN7L3</i> fusion define a novel high-risk subtype of B-cell ALL
|Blood|2022|34
Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Emerges from Preleukemic <i>TP53</i> -Mutant Clonal Hematopoiesis
|Blood Cancer Discovery|2023|33